Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
September 01 2022 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, announced today that its
collaboration with Dr. Iñaki Sanz at Emory University has led to a
publication in Nature, found here. Exagen’s clinical test
offerings, run on samples from severe COVID-19 patients, helped
researchers from Emory characterize the autoimmune profiles induced
by SARS-CoV-2 infection.
In addition, these retrospective analyses laid the groundwork
for the recent longitudinal studies of so-called post-acute COVID
syndrome (PACS), as well as other post-severe pulmonary infection
sequelae, including the incorporation of Exagen’s proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
These efforts will assess the importance of long-term autoimmune
monitoring in those patients experiencing lasting symptoms
following acute pulmonary infection, including those caused by
SARS-CoV-2.
Mathew Woodruff, PhD is a researcher at the Lowance Center for
Human Immunology and the Division of Rheumatology at Emory School
of Medicine. “We are excited to have partnered with Exagen on this
important work investigating the origins of emerging self-targeted
antibody responses in severe COVID-19. Their broad clinical testing
platforms have allowed us to identify unexpected markers of
dysregulated immunity and have uncovered new possibilities for
identifying patients that may benefit from targeted immune therapy.
We look forward to how our collaboration may help characterize the
complicated recovery phases of COVID-19 and identify potential
opportunities for medical intervention.”
“We are grateful to be able to partner with Emory University on
this work. The discoveries being made in uncovering these
unexpected markers and autoimmune profiles will mean relief to a
lot of people who are suffering. Whether it be recovering from
severe COVID-19 or other acute pulmonary infections, helping
identify the right therapy for patients is the step towards
personalized care that we want to see in all of rheumatology. This
publication marks an exciting step along that journey,” said Ron
Rocca, President and CEO of Exagen.
About Exagen Inc.
Exagen (Nasdaq: XGN) is a leading provider of autoimmune
diagnostic, prognostic, and monitoring testing
solutions. Exagen is a patient focused, discovery driven
organization built on the success of AVISE testing and is investing
in its product pipeline to support patients throughout their
autoimmune diagnosis and treatment journeys. The goal
at Exagen is to assist patients, physicians, and payors
by enabling precision medicine. Exagen is located
in San Diego County with clinical and research and
development laboratories in Vista, CA.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen’s
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements regarding the potential
utility and effectiveness of Exagen’s services and testing
solutions and regarding Exagen’s and Emory School of Medicine’s
interpretations of clinical study results and management’s views
and evaluations of the same. The inclusion of forward-looking
statements should not be regarded as a representation
by Exagen that any of its plans will be achieved. Actual
results may differ from those set forth in this press release due
to the risks and uncertainties inherent in Exagen’s business,
including, without limitation: the COVID-19 pandemic may continue
to adversely affect its business, financial condition and results
of operations, including as a result of slowdown in its operations
as well as those of its suppliers and courier services, impeding
patient movement and interruptions to healthcare services causing a
decrease in test volumes, disruptions to the supply chain of
material needed for its tests causing an increase in cost per test,
its sales and commercialization activities and its ability to
receive specimens and perform or deliver the results from its
tests, delays in reimbursement and coverage decisions from Medicare
and third-party payors and in interactions with regulatory
authorities, and delays in ongoing and planned clinical trials
involving its tests; Exagen’s commercial success depends upon
attaining and maintaining significant market acceptance of its
testing products and promoted therapeutics among rheumatologists,
patients, third-party payors and others in the medical community;
Exagen’s ability to successfully execute on its business
strategies; third-party payors not providing coverage and adequate
reimbursement for Exagen’s testing products or promoted
therapeutics, including Exagen’s ability to collect funds due;
expectations regarding its pipeline products, including the
development of the AVISE RADR platform; Exagen’s ability to obtain
and maintain intellectual property protection for its testing
products; regulatory developments affecting Exagen’s business; and
other risks described in Exagen’s prior press releases and Exagen’s
filings with the Securities and Exchange
Commission (“SEC”), including under the heading “Risk Factors”
in Exagen’s Annual Report on Form 10-K for the year
ended December 31, 2021 and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and Exagen undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date hereof. All forward-looking statements are
qualified in their entirety by this cautionary statement, which is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024